Literature DB >> 16930953

Verotoxin-1 stimulation of macrophage-like THP-1 cells up-regulates tissue factor expression through activation of c-Yes tyrosine kinase: Possible signal transduction in tissue factor up-regulation.

Kazuya Murata1, Toshiyuki Higuchi, Kimihiko Takada, Koji Oida, Shuichi Horie, Hidemi Ishii.   

Abstract

Verotoxin (VT)-producing Escherichia coli (E. coli) O157:H7 infections are frequently complicated by thrombotic angiopathy, hemolytic uremic syndrome (HUS) and neurological symptoms. The present data demonstrate that VT-1 (Shiga toxin) stimulation of macrophage-like THP-1 cells up-regulates the activity, antigen and mRNA levels of tissue factor (TF), a key cofactor of the coagulation-inflammation-thrombosis circuit. This up-regulation is accompanied by phosphorylation of phosphatidylinositol 3-kinase (PI3-kinase), IkappaB kinase beta (IKKbeta) and extracellular signal-regulated kinase 2 (ERK2). Changes in TF mRNA levels were in parallel with the activation of NF-kappaB/Rel and Egr-1 activation, but not with AP-1. Inhibition of PI3-kinase attenuated VT-1-induced phosphorylation of IKKbeta and ERK2, and the up-regulation of TF mRNA levels. VT-1 stimulation rapidly activated c-Yes tyrosine kinase, a member of the Src family. Treatment of the cells with c-Yes antisense oligos attenuated the VT-1-induced phosphorylation of PI3-kinase, IKKbeta and ERK2, activations of NF-kappaB/Rel and Egr-1, and up-regulation of TF mRNA levels. These results suggest that VT-1-induced macrophage stimulation activates c-Yes, which then up-regulates TF expression through activation of the IKKbeta/proteasome/NF-kappaB/Rel and MEK/ERK2/Egr-1 pathways via activation of PI3-kinase. Induction of macrophage TF expression by VT-1 may play an important role in the acceleration of the coagulation-inflammation-thrombosis circuit during infections by VT-producing E. coli.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16930953     DOI: 10.1016/j.bbadis.2006.07.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

Review 1.  Shiga toxins--from cell biology to biomedical applications.

Authors:  Ludger Johannes; Winfried Römer
Journal:  Nat Rev Microbiol       Date:  2009-12-21       Impact factor: 60.633

Review 2.  Shiga toxin pathogenesis: kidney complications and renal failure.

Authors:  Tom G Obrig; Diana Karpman
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

3.  Differential response of the human renal proximal tubular epithelial cell line HK-2 to Shiga toxin types 1 and 2.

Authors:  Erin K Lentz; Dinorah Leyva-Illades; Moo-Seung Lee; Rama P Cherla; Vernon L Tesh
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

Review 4.  Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction.

Authors:  Carla Zoja; Simona Buelli; Marina Morigi
Journal:  Pediatr Nephrol       Date:  2010-04-28       Impact factor: 3.714

Review 5.  Shiga toxins expressed by human pathogenic bacteria induce immune responses in host cells.

Authors:  Moo-Seung Lee; Myung Hee Kim; Vernon L Tesh
Journal:  J Microbiol       Date:  2013-12-19       Impact factor: 3.422

6.  Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome.

Authors:  Anne-lie Ståhl; Lisa Sartz; Anders Nelsson; Zivile D Békássy; Diana Karpman
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

Review 7.  Shiga Toxins as Multi-Functional Proteins: Induction of Host Cellular Stress Responses, Role in Pathogenesis and Therapeutic Applications.

Authors:  Moo-Seung Lee; Sunwoo Koo; Dae Gwin Jeong; Vernon L Tesh
Journal:  Toxins (Basel)       Date:  2016-03-17       Impact factor: 4.546

Review 8.  Microvesicle Involvement in Shiga Toxin-Associated Infection.

Authors:  Annie Villysson; Ashmita Tontanahal; Diana Karpman
Journal:  Toxins (Basel)       Date:  2017-11-19       Impact factor: 4.546

Review 9.  Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies.

Authors:  Lindsay S Keir; Stephen D Marks; Jon Jin Kim
Journal:  Drug Des Devel Ther       Date:  2012-07-19       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.